0000950134-01-507155.txt : 20011018
0000950134-01-507155.hdr.sgml : 20011018
ACCESSION NUMBER: 0000950134-01-507155
CONFORMED SUBMISSION TYPE: SC 13D
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20011010
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: REFSLAND EARL R
CENTRAL INDEX KEY: 0001160118
STANDARD INDUSTRIAL CLASSIFICATION: []
FILING VALUES:
FORM TYPE: SC 13D
BUSINESS ADDRESS:
STREET 1: 1720 SUBLETTE AVENUE
CITY: ST. LOUIS
STATE: MO
ZIP: 63110
MAIL ADDRESS:
STREET 1: 1720 SUBLETT AVENUE
CITY: ST. LOUIS
STATE: MO
ZIP: 63110
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: ALLIED HEALTHCARE PRODUCTS INC
CENTRAL INDEX KEY: 0000874710
STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
IRS NUMBER: 231370721
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
FILING VALUES:
FORM TYPE: SC 13D
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-43614
FILM NUMBER: 1756331
BUSINESS ADDRESS:
STREET 1: 1720 SUBLETTE AVE
CITY: ST LOUIS
STATE: MI
ZIP: 63110
BUSINESS PHONE: 3147712400
MAIL ADDRESS:
STREET 1: 1720 SUBLETTE AVENUE
CITY: ST LOUIS
STATE: MO
ZIP: 63110
SC 13D
1
c65407sc13d.txt
SCHEDULE 13D
1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. )*
ALLIED HEALTHCARE PRODUCTS, INC.
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK
--------------------------------------------------------------------------------
(Title of Class of Securities)
019222108
--------------------------------------------------------------------------------
(CUSIP Number)
CHARLES E. H. LUEDDE, ESQ.
10 SOUTH BROADWAY, SUITE 2000, ST. LOUIS, MISSOURI 63102 (314) 241-9090
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive
Notices and Communications)
SEPTEMBER 7, 2001
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(e), (f) or (g), check the following
box [ ].
NOTE. Schedules filed in paper format shall include a signed original
and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for
other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
2
--------------------------------------------------------------------------------
CUSIP No. 019222108 13D Page 2 of 4 Pages
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 Names of Reporting Persons/I.R.S. Identification Nos. of Above
Persons (entities only)
EARL R. REFSLAND
--------------------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group (See Instructions)
(a) [ ]
(b) [X]
--------------------------------------------------------------------------------
3 SEC Use Only
--------------------------------------------------------------------------------
4 Source of Funds (See Instructions)
OO
--------------------------------------------------------------------------------
5 Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 Citizenship or Place of Organization
UNITED STATES
--------------------------------------------------------------------------------
Number of 7 Sole Voting Power
Shares 419,425
---------------------------------------------------
Beneficially 8 Shared Voting Power
Owned by -0-
---------------------------------------------------
Each 9 Sole Dispositive Power
Reporting 419,425
---------------------------------------------------
10 Shared Dispositive Power
Person With
-0-
--------------------------------------------------------------------------------
11 Aggregate Amount Beneficially Owned by Each Reporting Person
419,425
--------------------------------------------------------------------------------
12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions) [ ]
--------------------------------------------------------------------------------
13 Percent of Class Represented by Amount in Row (11)
5.2%
--------------------------------------------------------------------------------
14 Type of Reporting Person (See Instructions)
IN
--------------------------------------------------------------------------------
3
--------------------------------------------------------------------------------
CUSIP No. 019222108 13D Page 3 of 4 Pages
--------------------------------------------------------------------------------
ITEM 1. Security and Issuer.
Common Stock, $.01 Par Value
Allied Healthcare Products, Inc.
1720 Sublette Avenue
St. Louis, MO 63110
ITEM 2. Identity and Background.
(a) Earl R. Refsland
(b) c/o Allied Healthcare Products, Inc.
1720 Sublette Avenue
St. Louis, MO 63110
(c) Mr. Refsland has served as President and Chief Executive Officer of
Allied Healthcare Products, Inc. since September 1999.
(d) Not applicable.
(e) Not applicable.
(f) Mr. Refsland is a citizen of the United States of America.
ITEM 3. Source and Amount of Funds and Other Consideration.
On August 24, 1999 Mr. Refsland was granted 542,000 non-qualified
options pursuant to the Issuer's 1999 Incentive Stock Option Plan. These options
are exercisable beginning December 7, 1999 in increments of 33,875 shares, on
the 7th of the last month of every three (3) month period thereafter through and
until September 7, 2003. The current number of exercisable options is 237,125.
Under the terms of the option agreement relating to such shares, such
options will expire unless exercised on or before August 23, 2009. These options
are exercisable at a price of $2.00 per share. At the time of the exercise of
such options, Mr. Refsland will be required to recognize as ordinary income an
amount per share equal to the difference between the exercise price and the fair
market value on the date of exercise and the Issuer will be entitled to a tax
deduction for a like amount.
Mr. Refsland acquired 27,800 shares of the Common Stock of the Issuer
on November 15, 1999 for $69,500 in cash, an additional 10,000 shares for
$29,400 on February 15, 2000, an additional 5,000 shares for $16,875 on March 3,
2000, an additional 5,000 shares for $15,000 on September 15, 2000, an
additional 14,500 shares for $43,500 on October 5, 2000, and an additional
120,000 shares for $330,000 on November 28, 2000. These purchases were all made
with cash and the funds used in making these purchases were from Mr. Refsland's
personal funds.
ITEM 4. Purpose of the Transaction.
Mr. Refsland's holdings of shares of the Common Stock of the Issuer
represent a continuing investment position in the operations of the Issuer and
are a result of purchases made by Mr. Refsland and incentive stock options
granted by the Issuer. Mr. Refsland does not presently contemplate the
acquisition of additional shares of the Common Stock of the Issuer except in
connection with the exercise of the non-statutory options described in Item 3
above. Mr. Refsland may from time to time engage in sales or other dispositions
of shares of the Common Stock of the Issuer in order to provide increased
liquidity and diversity to his portfolio and/or to provide funding for
anticipated income tax liabilities associated with the exercise of the
non-statutory options described in Item 3 above.
4
--------------------------------------------------------------------------------
CUSIP No. 019222108 13D Page 4 of 4 Pages
--------------------------------------------------------------------------------
ITEM 5. Interest in Securities of the Issuer.
(a) Earl R. Refsland 419,425* 5.2%**
* includes 237,125 shares which may be acquired upon exercise
of non-statutory options.
**percent of class is based upon: (i) number of shares of the
Issuer outstanding on September 30, 2001, plus (ii) the
shares which may be acquired under such non-statutory
options.
(b) Mr. Refsland has the power to vote his respective shares and has
dispositive powers.
(c) Pursuant to the terms of the Issuer's 1999 Incentive Stock Plan,
33,875 options became exercisable by Mr. Refsland on September 7, 2001.
(d) Not applicable.
(e) Not applicable.
ITEM 6. Contracts, Arrangements, Understandings or Relationships With Respect to
Securities of the Issuer.
Not applicable.
ITEM 7. Material to be Filed as Exhibits.
Not applicable.
After reasonable inquiry, and to the best of the undersigneds'
knowledge and belief, the undersigned certify that the information set forth in
this statement is true, complete and correct.
/s/ Earl R. Refsland
-------------------------------------
Earl R. Refsland
Date: October 10, 2001